Showing 1741-1750 of 2105 results for "".
- Lamotrigine, Levetiracetam and Other Antiseizure Medications During Pregnancy Not Associated With Developmental Delays at Age 3 Yearshttps://practicalneurology.com/news/lamotrigine-levetiracetam-and-other-antiseizure-medications-during-pregnancy-not-associated-with-developmental-delays-at-age-3-years/2469520/According to a preliminary study, children born to women taking certain antiseizure medications (ASMs) for epilepsy during pregnancy had no higher risk of developmental delays at age 3 years when compared with children of women without epilepsy. The study involved 275 individuals
- Kidney Problems as a Young Adult May Affect Cognitive Function in Midlifehttps://practicalneurology.com/news/kidney-problems-as-a-young-adult-may-affect-cognitive-function-in-midlife/2469370/Individuals may experience worse cognitive function during midlife if they had moderate-to-high risk of kidney failure as a young adult, according to a study published in Neurology. “We know that people wit
- Children With Duchenne Muscular Dystrophy Receiving Ataluren Treatment Were Able to Walk Independently for an Additional 3.5 Yearshttps://practicalneurology.com/news/children-with-duchenne-muscular-dystrophy-receiving-ataluren-treatment-were-able-to-walk-independently-for-an-additional-35-years/2469147/Real-world data showing that boys with Duchenne muscular dystrophy (DMD) treated with ataluren (Translarn, PTC Therapeutics, Inc., South Plainfield, NJ) preserved the ability to walk for 3.5 years longer than given standard-of-care (SoC) treatment alone. Pulmonary function was also preserved in t
- Young Black and Latino People May Fare Better Than Whites After Hemorrhagic Strokehttps://practicalneurology.com/news/young-black-and-latino-people-may-fare-better-than-whites-after-hemorrhagic-stroke/2469136/Young black and Latino people may be less likely than young white people to be disabled or even die within 3 months of a hemorrhagic stroke. This is reported in a clinical study published in Neurology, which focused on younger people who have had hemorrhagic stroke. Of whites in the stu
- Concussion Effects May Linger More Than a Year After Return to Playhttps://practicalneurology.com/news/concussion-effects-may-linger-more-than-a-year-after-return-to-play/2469051/New research published in Neurology has found athletes’ brains may still not be fully recovered 1 year after being allowed to return to play. The study involved 24 college athletes with concuss
- Gene Therapy for Children Age 6 Months to 5 Years with Spinal Muscular Atrophy Type 2 Effective in Clinical Trialhttps://practicalneurology.com/news/gene-therapy-for-children-age-6-months-to-5-years-with-spinal-muscular-atrophy-type-2-effective-in-clinical-trial/2469042/Children age 6 months to 5 years with spinal muscular atrophy (SMA), treated with onasemnogene (AVXS-101; Zolgensma, Bannockburn, IL) are showing improvements in motor function. In the STRONG (NCT03381729) phase 1/2 clinical study, 1 of
- Children with Spinal Muscular Atrophy Who Were Treated With Single-Dose Gene Therapy Continue Making Clinical Gainshttps://practicalneurology.com/news/children-with-spinal-muscular-atrophy-who-were-treated-with-single-dose-gene-therapy-continue-making-clinical-gains/2469026/Children treated with single-dose gene replacement therapy (Zolgensma; Avexis, Bannockburn, IL) for spinal muscular atrophy (SMA) continue meeting development milestones in the phase 3 SPR1NT clinical trial (NCT03505099). Treatment was
- Parkinson’s IQ + You Events Provide Support for All Affected by the Disorderhttps://practicalneurology.com/news/parkinsons-iq-you-events-support-provide-support-for-all-affected-by-the-disorder/2468940/A series of events titled Parkinson’s IQ + You will be taking place at locations across the US throughout 2019 and 2020. These events are designed to help people with Parkinson's disease (PD) and their care partners manage the effects of PD, learn about research, and connect with local
- Zolgensma Approved and Available to Treat All Types of Spinal Muscular Atrophy in Babies Under Age 2 Yearshttps://practicalneurology.com/news/zolgensma-approved-and-available-to-treat-all-types-of-spinal-muscular-atrophy-in-babies-under-age-2-years/2468911/The Food and Drug Administration (FDA) has approved onasemnogene abeparvovac-xioi (Zolgensma; Avexis, Bannockburn, IL) for the treatment of all types of spinal muscular atrophy (SMA) in children under age 2 years. Approved indications for onasemnogene, an SMN gene-replacement therapy, include all
- Young Blood Plasma for Parkinson's Diseasehttps://practicalneurology.com/news/young-blood-plasma-causes-neurological-improvement-in-parkinsons-disease-patients/2468880/Results of a clinical trial that administered blood plasma from donors, age 18 to 25 years, into individuals with Parkinson's disease resulted in significant improvements in neurologic assessments. After 3 months, patients showed improvements in motor